[go: up one dir, main page]

PE20181332A1 - Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos - Google Patents

Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos

Info

Publication number
PE20181332A1
PE20181332A1 PE2018000199A PE2018000199A PE20181332A1 PE 20181332 A1 PE20181332 A1 PE 20181332A1 PE 2018000199 A PE2018000199 A PE 2018000199A PE 2018000199 A PE2018000199 A PE 2018000199A PE 20181332 A1 PE20181332 A1 PE 20181332A1
Authority
PE
Peru
Prior art keywords
sedation
treatment
methods
use during
critical care
Prior art date
Application number
PE2018000199A
Other languages
English (en)
Inventor
Matthew During
Anna Kazanchyan
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/834,027 external-priority patent/US9399034B1/en
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of PE20181332A1 publication Critical patent/PE20181332A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere a una composicion farmaceutica de gaboxadol o su sal farmaceuticamente aceptable, en el que se utiliza para sedar a un paciente humano durante el tratamiento en un entorno de cuidados intensivos, en la que se administra por via intravenosa. Proporciona un perfil plasmatico in vivo que comprende una Cmax de menos de aproximadamente 3500ng/ml en el que el paciente permanece despierto y orientado. Tambien se refiere a formulaciones parenterales.
PE2018000199A 2015-08-11 2016-08-02 Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos PE20181332A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562203731P 2015-08-11 2015-08-11
US201562203748P 2015-08-11 2015-08-11
US14/834,027 US9399034B1 (en) 2015-08-11 2015-08-24 Methods of sedation during critical care treatment
US15/185,650 US9717716B2 (en) 2015-08-11 2016-06-17 Methods of sedation during critical care treatment

Publications (1)

Publication Number Publication Date
PE20181332A1 true PE20181332A1 (es) 2018-08-20

Family

ID=59687449

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000199A PE20181332A1 (es) 2015-08-11 2016-08-02 Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos

Country Status (12)

Country Link
US (1) US20180235942A1 (es)
EP (1) EP3334427A4 (es)
JP (1) JP6857647B2 (es)
KR (1) KR20180048707A (es)
CN (1) CN108135889A (es)
AU (1) AU2016304737B2 (es)
CA (1) CA2994952A1 (es)
CO (1) CO2018002534A2 (es)
IL (1) IL257296B2 (es)
MX (1) MX394213B (es)
PE (1) PE20181332A1 (es)
TW (1) TWI763632B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018000933A2 (pt) 2015-07-17 2018-09-04 Ovid Therapeutics Inc métodos de tratamento de um distúrbio de desenvolvimento
KR102518846B1 (ko) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
KR20210062662A (ko) 2018-09-20 2021-05-31 오비드 테라퓨틱스 인크. 투렛 증후군, 틱들 및 말더듬의 치료를 위한 가복사돌의 사용
CN113395962A (zh) 2018-11-21 2021-09-14 Certego治疗公司 加波沙朵用于降低自杀风险和快速缓解抑郁症
US11690829B2 (en) 2018-12-17 2023-07-04 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
US20220218740A1 (en) * 2020-10-25 2022-07-14 Vaporworks Nursing Anesthesia Inc. Opioid-free compositions for anesthesiological applications and related methods and systems

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071933A (en) * 1999-12-03 2000-06-06 Diversified Medical Innovations, Inc. Homogeneous remifentanil-propofol blend for patient controlled anesthesia and process for its use
WO2005063248A1 (en) * 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
ATE454140T1 (de) * 2004-02-18 2010-01-15 Sepracor Inc Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
US9399034B1 (en) * 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Also Published As

Publication number Publication date
MX2018001720A (es) 2018-09-06
AU2016304737B2 (en) 2021-03-11
AU2016304737A1 (en) 2018-02-22
KR20180048707A (ko) 2018-05-10
US20180235942A1 (en) 2018-08-23
TW201717944A (zh) 2017-06-01
CN108135889A (zh) 2018-06-08
IL257296B2 (en) 2023-02-01
CA2994952A1 (en) 2017-02-16
JP2018522920A (ja) 2018-08-16
EP3334427A1 (en) 2018-06-20
IL257296A (en) 2018-03-29
TWI763632B (zh) 2022-05-11
MX394213B (es) 2025-03-24
EP3334427A4 (en) 2019-02-06
IL257296B (en) 2022-10-01
JP6857647B2 (ja) 2021-04-14
CO2018002534A2 (es) 2018-05-31

Similar Documents

Publication Publication Date Title
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
MX392606B (es) Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
MX2024010140A (es) Nuevos metodos.
PE20170302A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX377576B (es) Formulaciones de pridopidina de liberación modificada.
SMT201300095B (it) Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
PH12014500386A1 (en) Combination treatment for hepatitis c
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
EA201890507A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
MX2015014939A (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
NI201200196A (es) Agentes terapéuticos 976
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
MX372644B (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.
EA201592261A1 (ru) Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой
AR114012A1 (es) Método para proporcionar terapia de celiprolol a un paciente
MX375018B (es) Combinación de ácido docosahexaenoico e indometacina para su uso como analgésico.

Legal Events

Date Code Title Description
FD Application declared void or lapsed